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Summary
T lymphocytes and eosinophils are important components of the inflammatory cell infiltrate in
bronchial mucosa in asthma. Because activated lymphocytes migrate through the thoracic duct
and the general circulation to remote glandular and mucosal sites, we initiated this study to
evaluate pathological abnormalities and immunoreactivity for interleukin (IL) 3, IL-5, and
granulocyte/macrophage colony-stimulating factor (GM-CSF) ofintestinal mucosa in bronchial
asthma. 15 asthmatic patients, 8 nonasthmatic patients with chronic obstructive pulmonary dis-
ease, 6 atopic nonasthmatic healthy controls, and 6 nonatopic healthy controls were studied.
Duodenal biopsies were performed by endoscopy. A significantly increased number of intra-
epithelial lymphocytes and eosinophils and a significant accumulation of mononuclear cells
(lymphocytes and mast cells) and eosinophils in the lamina propria were detected in asthmatics
and atopic controls. Immunostaining with antibodies directed against IL-3, IL-5, and GM-CSF
was positive in asthmatics and atopic controls, whereas no staining was observed in nonatopic
controls and chronic obstructive pulmonary disease. Combined ultrastructural study and immu-
nogold labeling demonstrated that IL-3, IL-5, and GM-CSF were localized in eosinophils and
mast cells. Although devoid of gastrointestinal symptoms, asthmatics and asymptomatic atopics
had duodenal pathological abnormalities mimicking those observed in the bronchial mucosa in
asthma, suggesting that the whole mucosal immune system is involved in bronchial asthma.
I
n bronchial asthma, the chronic inflammation of the air-
ways is an important feature that underlies the broncho-
constriction and bronchial hyperresponsiveness characteris-
tic of the disease. Recent studies have emphasized the
potential role of lymphocytes in the pathogenesis of asthma
(1) : (a) T lymphocyte, predominantly CD4+, cell infiltrate
has been demonstrated in bronchial biopsies in chronic
asthma; and (b) the modulation of bronchial inflammation
is exerted through the release of lymphokines. IL-3, IL-5,
and GM-CSF are of particular importance in the develop-
ment and activation of eosinophils and mast cells, which
are constantly found in the bronchial mucosa of asthmatics
(1-4). In addition, eosinophils and mast cells can them-
selves synthesize IL-3, IL-5, and GM-CSF, which can af-
fect their own functioning and interact with lymphocytes,
neutrophils, or macrophages (5-9) .
The mucosal immune system comprises a series of spe-
cialized lymphoid tissues having the complex task of pro-
tecting the most vulnerable surfaces of the body that inter-
act with the external environment (10) . Both lung and gut
possess mucosa-associated lymphoid tissues, and there is a
selective traffic of lymphocytes between them. Animal ex-
periments have demonstrated that precursors originating
from bronchus-associated lymphoid tissue may migrate to
the intestinal mucosa and other sites with mucosa-associ-
ated lymphoid tissue (11). Sensitization of bronchus-associ-
ated lymphocytes may thus be responsible for the induction
of an immune response in the minor salivary glands (12) .
Along this line, we recently demonstrated an airway-like
inflammation of the minor salivary glands of patients with
asthma (13) . The proposed explanation is that activated
lymphocytes that have the ability to recognize specific anti-
gens in bronchial mucosal lymphoid tissue might migrate
through the thoracic duct and the systemic circulation to
other glandular and mucosal sites. According to this con-
cept of homing of specific lymphocytes, it was reasonable
to hypothesize that a similar airway-like inflammation
might occur in other mucosal tissues of asthmatics. To es-
1897
￿
J. Exp. Med. © The Rockefeller University Press " 0022-1007/95/12/1897/08$2.00
Volume 182 December 1995 1897-1904Table 1.
￿
Characteristics of 15 Patients with Bronchial Asthma, 8 Patients with COPD, 6 Nonatopic Healthy Controls, and 6 Atopic
Healthy Controls
Number
Sex ratio (female/male)
Age (mean ± SEM)
Positive cutaneous prick tests
Total IgE (IU/ml)
FEV, (% predicted)
Blood eosinophils (per mm')
Oral steroids therapy (number)
Inhaled steroids (number)
Asthmatics
15
6/9
44 - 4.1
7
401 ± 120$
78±6
216 ± 44*
7
11
Cutaneousprick test was defined as positive when the wheal size was similar or superior to the positive control (histamine).
*Significantly different from the other groups.
$Significantly differentfrom COPD and nonatopic controls.
§Significantly differentfrom asthmatics andCOPD (P <0.05).
tablish this, we initiated a prospective study of the immu-
nopathological abnormalities of gut mucosa in 15 patients
with bronchial asthma, free of symptoms of gastrointestinal
disease. Our results clearly demonstrated the presence of an
airway-like inflammation of gut mucosa in asthmatics and
atopic healthycontrols as judged by both an increased num-
ber oflymphocytes, plasma cells, eosinophils, andmast cells
in the lamina propria, and an immunoreactivity for IL-3,
IL-5, and GM-CSF in the gut mucosa, which was not ob-
served in the control groups.
Materials and Methods
15 nonsmoking patients with asthma andwithout symptoms of
gastrointestinal disease were included in the study. Patients with a
familial history of inflammatory bowel disease were excluded
from the study. In addition, to exclude coeliac disease, measure-
ments of IgG and IgA antighadin and antiendomysium Abs were
performed and were negative in all patients. There were six
women and nine men. The mean age was 44 ± 4.1 yr and the
range was from 15 to 64 yr. Asthma was definedaccording to the
criteria of the international consensus report on diagnosis and
management of asthma (14) . All patients exhibited a history of
episodes of dyspnea and wheezes and had a reversible airway ob-
struction characterizedby a 20% increase in forced expiratory vol-
ume in 1 s (FEV,) I after the inhalation of 200 N.g of albuterol. All
patients were studied in the same manner. Sensitivity to allergens,
including a battery ofextracts ofcommon aeroallergens, was eval-
uated by skin-prick tests. Skin-prick tests were negative for food
allergen. Total serum IgE levels (Phadebas paper radioimmuno-
sorbent test, Pharmacia Diagnostics, St. Quentin-Yvelines, France)
was determined. Serum-specific IgE was measured by the Phade-
bas radioallergosorbent test (Pharmacia Diagnostics) in patients
with positive skin-prick tests. Seven patients had allergic asthma
and eight had nonallergic asthma. None of the patients had clini-
'Abbreviations used in this paper: COPD, chronic obstructive pulmonary
disease; FEVI, forced expiratory volume in 1 s; GSE, gluten-sensitive en-
teropathy.
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COPD
￿
Nonatopic controls
￿
Atopic controls
8
￿
6
￿
6
1/7
￿
3/3
￿
3/3
58 -}3.2*
￿
46±2
￿
44±3.1
0
￿
0
￿
6
124 ± 102
￿
92 ±- 12
￿
329 ± 150$
71 ± 4
￿
104 ± 2§
￿
101 ± 2§
45±16
￿
62±24
￿
54±22
2
￿
0
￿
0
0
￿
0
￿
0
cal signs of eczema at the time of the study. All patients had nor-
mal sinus and chest x-ray films. All patients were studied forpul-
monary function tests. FEV, was determined using a spirometer
(Jaeger Hellige, Strasbourg, France). Regular medications were
taken by 11 out of 15 patients: seven patients were treated with
inhaled steroids andoral steroids at amean dose of18.4 ± 3 mg/d
at the time of the study, and four received inhaled steroids. All
patients also received intermittent inhaled short-acting R2-ago-
nist, taken as needed. The clinical severity of asthma was assessed
according to the international report: mild (four cases), moderate
(four cases), and severe (seven cases) . Characteristics of the pa-
tients are summarized in Table 1.
We also studied eight nonasthmatic smoking patients with
chronic obstructive pulmonary disease (COPD), and six atopic
asymptomatic nonasthmatic healthy subjects, and six nonatopic
healthy subjects as control groups. They had no allergic diseases
and had never had asthma. All COPD were treated with inter-
mittent inhaledanticholinergics.
Each patient signed an informed consent statement, and the
protocol was approved by the Lille CHRU hospital's ethical
committee (CP 94/34) .
Duodenal Biopsies.
￿
Gastroduodenal endoscopy was performed
in all subjects. No endoscopic lesion was found. Systematic biop-
sies were performed in the duodenum. Intestinal fragments were
properly oriented to avoid tangential sectioning artifact, fixed im-
mediately in fresh 4% paraformaldehyde/PBS, and further pro-
cessed for paraffin embedding. Paraffin blocks were sectioned at
4 I.tm for histochemistry and immunolabeling. Pathological study
was performed on hematoxylin-eosin and May-Griinwald-Giemsa
stains to assess the gut architecture andthe number o£mononuclear
cells, including lymphocytes, in the epithelium and lamina pro-
pria. Indirect immunoenzymatic methods were used to identify
eosinophils and mast cells with mAbs directed against the eosino-
phil peroxidase (Oncogene Science Inc., Uniondale, NY) andthe
human tryptase (Chemicon International, Inc., Temecula, CA), re-
spectively. Assessment of architectural mucosal abnormalities was
graded as normal, partial villous atrophy, and total villous atrophy.
The pattern of cellular mucosal change was determined blindly by
two different pathologists, without knowledge of the clinical data,
on similar areas in the different biopsies. The number ofintraepi-thelial lymphocytes was expressed per 100 epithelial cells. The
number ofinflammatory cells in the lamina propria was expressed
for a surface of 104 wmz oflamina propria. Cell counts were based
on an individually defined mucosal tissue unit constituting a4-N.m-
thickand 500-p,m block of tissue overlying 200 ~Lm of muscularis
mucosae (15) . The presence of IL-3, IL-5, and GM-CSF proteins
was detected with polyclonal rabbit Abs directed against human
IL-3, human IL-5, and humanGM-CSF (all from Genzyme Corp.,
Cambridge, MA). These Abs were used at 1/50 for the IL-3 and
GM-CSF immunolabeling and at 1/250 for IL-5 detection. After
incubation for 45 min at room temperature, slides were briefly
washed in TBS. The bindingwas detected by means of streptavi-
din complex (LSAB2 Kit, Alkaline Phosphatase; Dako Corp.,
Copenhagen, Denmark). Enzymatic complex, alkaline phosphatase,
anti-alkaline phosphatase, was added at a 1/50 dilution and devel-
oped with phosphate substrate and neofuscin (Sigma Chemical
Co., St. Louis, MO). Forimmunochemistry, controls included: (a)
omission of the first Ab, and (b) substitution of the first Ab by an
irrelevant Ab of the same isotype but with a different specificity
(anti-Echinococcusgranulosus).
Electron Microscopy.
￿
Duodenal biopsies were immediately fixed
in 2% glutaraldehyde in cacodylate buffer. Half of the specimens
were embedded in epon andprocessedfurther for conventional elec-
tron microscopy. The otherspecimens were embedded in Lowic-
rylK4M (Oxford, Orsay, France) for immunocolloidalgold labeling.
Utrastructural Immuncgold Labelings.
￿
Ultrathinsections on nickel
grids were incubated for 10 min on a drop of Tris-HCl-buffered
saline (20 mmol/liter Tris-HCI, 0-5 mol/titer NaCl) (TBS), pH
7.4, containing 5% (wt/vol) ovalbumin, supplemented with 1%
heat-inactivated normal goat serum. This was followed by incu-
bation with polyclonal rabbit Abs to human IL-3, IL-5, and GM-
CSF used as primary reagents. The grids were then rinsed with
TBS-ovalbumin and incubated on a drop of the 1-nm gold-con-
jugated goat anti-rabbit IgG (1/50). After 1 hour ofincubation at
room temperature, sections were thoroughly washed with TBS,
postftxed for 10 min in distilled water containing 1% glutaralde-
hyde and washed again with distilled water. Finally, the sections
were subjectedto silver enhancement according to a modification
of Danscher's silver lactate hydroquinone (Sigma Co., St. Quen-
tin Fallavier, France) physical developer. The specificity of the
immunostaining was tested by omitting the first Ab and substitut-
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*Results are expressed as the number ofinflammatory intraepithelial cells per 100 epithelial cells (mean ± SEM) .
$Significantly different from COPD and nonatopic controls.
§Results are expressed as number ofcells per 104 wm2 muscularis mucosae (mean ± SEM).
ing the specific Abs with the preimmune serum or with unrelated
Abs whose labeling had been analyzed previously. To exclude
nonspecific binding to proteoglycans, additional control was per-
formed with an Ab directed against a toxoplasmic amylopectin
used as primaryAb. No gold deposit was observed. Lowicryl sec-
tions were contrasted with uranyl acetate before examination
with an electron microscope (EM 10; Carl Zeiss Ltd., Welwyn
Garden City, UK).
Statistical Analysis.
￿
Statistical analyses were performed with a
computer (Macintosh;Apple Co., Cupertino, CA) using the Star-
view II Software (Statview, Abacus Concepts, Inc., Berkeley, CA).
When applicable, data were expressed as mean ± SEM. The
Kruskal-Wallis analysis of variance procedure was applied first to
the quantitative data of the four groups. When this was signifi-
cant, each pairing was examined by means ofthe Mann Whitney
U test. Only Pvalues <0.05 were considered significant.
Results
Results of the immunopathological analysis ofendoscop-
ically normal areas in patients and controls are summarized
in Table 2.
Architectural mucosal abnormalities (partial villous atro-
phy) were observed in the intestinal mucosa of three pa-
tients with asthma but not in the patients from the control
groups. Significant cellular mucosal changes were detected
in the gut of the patients with asthma and atopic controls
when compared with COPD or nonatopic controls. The
villous epithelium was infiltrated by a significantly increased
number of lymphocytes and eosinophils in asthmatics and
atopic controls (Table 2) . The lamina propria was infiltrated
by a significantly increased number of mononuclear cells,
includinglymphocytes and mast cells, andan increased num-
ber ofeosinophils statistically different from control biopsies.
No neutrophils were counted on the studied areas. Ultra-
structural examination of the duodenal biopsies in asthmat-
ics showed numerous eosinophils and mast cells associated
with lymphocytes in the lamina propria. The fine structure
of eosinophil granules was altered. Most intracytoplasmic
Table 2. Pathological Abnormalities
and Atopic Healthy Controls
ofthe Gut Mucosa in Asthmatics, Patients with COPD, Nonatopic Healthy Controls,
Asthmatics COPD Nonatopic controls Atopic controls
Epithelium*
Intraepithelial lymphocytes 37.3 ± 3.8$ 13.5±0.9 11 .4±4 24.5{- 4.4$
Intraepithelial eosinophils 2.5 ± 0.8$ 0.2 ± 0.2 0 0.8 ± 0.4$
Lamina Propria§
Mononuclear cells 115.6 ± 8$ 52±6.2 51.8±6 99±6.7$
Lymphocytes 61 .4 ± 3.2$ 27.5±0.7 24±0.9 54±5.7$
Mast cells 3.3 ± 0.6$ 1.5 ± 0.4 1.3 ± 0.3 3.1 ± 0.2$
Eosinophils 12.1 ± 1.2$ 0.5±0.4 0.5±0.2 11 .1-±-1 .8$Figure 1 .
￿
Ultrastructural aspect of the infiltrate
of the lamina propria in an asthmatic patient. Eosi-
nophils (Eo) and mast cells (M) associated with
lymphocytes (L) . The arrows show free extracellu-
lar eosinophil granules .
Figure 2 .
￿
Representative IL-5 immunochemistry ofthe lamina propria gut mucosa in an asthmatic patient (left) and a patient withCOPD (right) . Indi-
rect immunophosphatase X400.
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Inflammation ofGut Mucosa in Asthmagranules had an inverted density of their central core (Fig .
1), but numerous free extracellular eosinophil granules
showed similar alterations .
By immunohistochemistry, cells stained with the Ab di-
rected against IL-5 (mean 6.2, range 0-15) (Fig . 2) were
slightly more numerous than the cells stained with the Ab
directed against IL-3 (mean 4.5, range 0-12) and against
GM-CSF (mean 5.3, range 0-13) (Fig. 3) . This labeling was
significantly higher in asthmatics than in COPD and non-
atopic controls . Interestingly, cells from atopic controls also
stained with the Ab directed against IL-5, IL-3, and GM-
CSF . No significant staining was observed in the mucosa of
patients with COPD or nonatopic controls . Controls with-
out the first Ab or with an irrelevant Ab were negative .
Combined ultrastructural examination with immunogold
stainings showed dense deposits within the eosinophil gran-
ules with Abs directed against IL-3, IL-5, and GM-CSF .
When the granules were not altered, the dense deposits were
located in the granule matrix, around the central core, as il-
lustrated for IL-5 in Fig . 4 . Dense deposits were also found
within mast cell granules with the three Abs . They were
localized over the whole surface of electron-dense granules,
as illustrated in Fig. 5 for GM-CSF . No immunolabeling of
lymphocytes was found .
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Figure 3 .
￿
Number of IL-3, IL-5, and
GM-CSF immunoreactive cells per 10°
N,mz of muscularis mucosae in duodenal
biopsies of patients with bronchial
asthma, patients with COPD, nonatopic
healthy controls, and atopic healthy
controls .
Allergic and nonallergic asthmatics had no significant dif-
ferences in their immunopathological features (Table 3) .
Lymphocyte and mononuclear cell counts and density ofthe
infiltrate of the lamina propria did not differ according to
the treatment . However, patients treated with oral steroid
(severe asthma) had a significantly lower number of eosino-
phils and mast cells than asthmatic patients treated with in-
haled steroids (moderate asthma) or untreated patients
(mild asthma) . Similarly, the number of cells stained with
the Ab directed against IL-3, IL-5, and GM-CSF was sig-
nificantly lower in patients with severe asthma than in pa-
tients with moderate or mild asthma.
Discussion
The purpose ofthis study was to assess the immunoreac-
tivity ofthe intestinal mucosa in asthmatics and therefore to
gain some insight into the common immune mocusal sys-
tem in humans . Experimental data have clearly provided
evidence for extensive migratory patterns to and between
mucosal sites that are collectively called the mucosa-associ-
ated lymphoid tissue (16, 17) . Our results demonstrated
significant pathological abnormalities, i.e ., airway-like in-
flammation of gut mucosa in asthmatics and atopic controls
free of gastrointestinal symptoms .
Figure 4 . Immunostaining with -immunogold-labeled
anti-IL-5 Ab . The dark deposits are localized in the matrix
ofthe intact eosinophil granules (arrows) .
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Ultrastructural aspect of mast cell (M) . Inset : inununostain-
ing with inununogold-labeled anti-GM-CSF Ab . Dark deposits are local-
ized within dense granules and at the periphery of the less dense granules
(arrows) .
The presence ofoccasional leukocytes in the lamina pro-
pria of the proximal duodenum is of doubtful significance .
Histological examination ofproximal duodenal biopsies ob-
tained from apparently normal duodenam might reveal a
slight to moderate increase in lamina propria cell content
(18) . However, the fact that immunoreactivity for IL-3,
IL-5, and GM-CSF was not detected in COPD and non-
atopic controls strongly supports the reality of the inflam-
matory process ofgut mucosa in asthmatics . In addition, bi-
opsies ofthe proximal duodenum accurately reflect thejejunal
and distal duodenum in both health and disease (19) . This
suggests that abnormalities ofgut mucosa in asthma are not
restricted to small duodenal areas .
We report for the first time histological changes and cy-
tokine production in the duodenum ofpatients with asthma
similar to those described in bronchial mucosa . Develop-
ment of fiberoptic bronchoscopy has provided an opportu-
nity to obtain bronchial mucosal biopsy specimens from
patients with asthma and to characterize features of airway
mucosal inflammation (1) . Previous observations indicated
that the bronchial epithelium and lamina propria of asth-
matics are infiltrated with increased numbers ofintraepithe-
lial lymphocytes, mast cells, eosinophils, and T lymphocytes
(20-22) . In this paper, we described a similar inflammatory
process of gut mucosa in asthma . In addition, mimicking
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matics, immunoreactivity ofgut mucosa for IL-3, IL-5, and
GM-CSF was demonstrated in asthmatics. Duodenal biop-
sies in COPD and nonatopic controls did not express immu-
noreactivity for any of the cytokines tested. More than one
gut lamina propria cell population expressed immunoreac-
tivity for IL-3, IL-5, and GM-CSF. Combined immu-
nogold staining and ultrastructural examination showed
that the three tested cytokines were localized in the matrix
of eosinophil granules and in cytoplasmic granules of mast
cells. Interestingly, ultrastructural studies showed that im-
munogold labeled five times more eosinophils than mast
cells and that no immunolabeling of lymphocytes was
found. It is well known that eosinophils and mast cells ex-
press cytokines. However, previous in situ hybridization
studies in bronchial biopsies demonstrated that both eosi-
nophils and lymphocytes expressed these cytokines (2, 3) .
The fact that gut mucosa lymphocytes did not express im-
munoreactivity of IL-3, IL-5, and GM-CSF is not clear.
This discrepancy of expression of lymphokines by lympho-
cytes in bronchial and gut mucosa might explain the differ-
ent clinical expression of mucosal reactivity in asthma.
The role of these cytokines in the gut mucosa of asth-
matics has not been fully elucidated. IL-3, IL-5, and GM-
CSF are important regulators of eosinophil survival, prolif-
eration, and effector function. Particularly, IL-5 is the main
mediator for eosinophil recruitment and activation and sup-
ports the proliferation and terminal differentiation of eosi-
nophil precursors as well as the prolonged survival of eosi-
nophils in vitro. However, these cytokines might also play
a role in modulating the immune response at mucosal sites.
IL-5 up-regulates IL-2 receptors and may potentiate the se-
cretion of IgA and other immunoglobulins (23) .
Strikingly, the histological and inununohistochemical find-
ings of the gut mucosa in asthma are reminiscent of those
previously observed in the duodenal mucosa o£patients with
coeliac disease (6, 24) and more generally in gluten-sensi-
tive enteropathy (GSE), classically characterized by a lym-
phoid infiltration of the epithelium and a lamina propria
edema with increase in lymphocytes, plasma cells, mast cells,
and eosinophils (25) . Moreover, we have recently shown
that eosinophils are the main source of IL-5 synthesis in the
mucosa of patients with GSE (6) . Polanco et al. have also
shown that bronchial asthma is associated with coeliac disease
as frequently as with dermatitis herpetiformis (26). However,
asthmatic patients in the present study had no clinical symp-
toms ofcoeliac disease, no or few architectural gut abnormal-
ities, and absence ofabnormal Ab titers against gliadin or en-
domysium, which are sensitive and specific markers ofGSE.
Mucosal lesions in GSE are mainly ascribed to T cells. Sim-
ilar mucosal changes are also found in other diseases in which
T cell-mediated activity toward environmental antigens is
likely, such as food allergy. As bronchial asthma is also con-
sistent with a T cell-mediated disease, we hypothesized
that the mechanisms responsible for the gut lesions in pa-
tients with asthma are similar to those involved in GSE.
The significance of the pathological abnormalities of the
gut mucosa in bronchial asthma can be discussed. The char-
acteristics of the inflammatory process of the gut mucosa
did not differ between allergic and nonallergic asthma. The
changes observed in gut mucosa of patients with severe
asthma are more likely due to the systematic treatment with
oral steroids than to the severity ofthe disease, since gluco-
corticoids are known to inhibit cytokine-mediated eosino-
phil survival (27) .
Our results raise several hypotheses that are not mutually
exclusive. First, there is some evidence that, when an anti-
gen is inhaled, a large proportion of it is rapidly translocated
into the gastrointestinal tract. In this context, it might be re-
sponsible for the development of an inflammatory response
of the gut mucosa. In animal experiments, it has been dem-
onstrated that, in response to an inhaled antigen sensitiza-
tion, induction of IgE-secreting cells was observed in both
lung and gut (28, 29). Second, the bronchus-associated lym-
phoid tissue generates both T and B lymphocyte immunity
in response to luminal antigen locally, but also at distinct mu-
cosal sites (30). Thus, inflammation of gut mucosa might also
result from a "bronchus to gut" flow of inflammatory cells.
Third, one cannot exclude that pathological abnormalities
are, at least in part, related to a primary dysfunction of the
mucosal immune system characteristic ofbronchial asthma.
The fact that both asthmatics and atopic healthy controls
exhibited the same pathological abnormalities supports the
hypothesis that atopy alone is sufficient to elicit the inflam-
matory changes in intestinal mucosa and that this inflam-
matory process relates to trafficking of cells rather than to
the ingestion ofallergen from various routes. Development
of obvious clinical symptoms then depends on the local
triggering by specific antigens. Whatever the mechanism,
our result supports the hypothesis that the common im-
mune mucosal system is involved, as a cause or as a conse-
quence, in bronchial asthma.
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